Lone Star Funds Announces Agreement to Acquire the Specialty Chemicals and High Performance Polymers Business Areas of RadiciGroup
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Specialty Chemicals and High Performance Polymers Business Areas of RadiciGroup, a leading global player in the chemical sector.
RadiciGroup, founded in 1941 and headquartered in Bergamo, Italy, is a family-owned company that has established itself as a global leader in the polyamides (nylon) value chain. With an agile business model and a high degree of specialization, RadiciGroup has become a trusted partner serving customers in Europe, the Americas and Asia across the automotive, industrial, electrics/electronics and consumer goods markets.
Lone Star will acquire the Specialty Chemicals and High Performance Polymers Business Areas, while the Radici family will retain control of the Advanced Textiles Solutions Business Area.
“RadiciGroup has a proven track record of innovation, quality and customer commitment, making it a natural addition to Lone Star’s portfolio,” said Donald Quintin, Chief Executive Officer of Lone Star. “This carve-out acquisition is highly complementary to Lone Star’s portfolio of specialty chemicals and manufacturing businesses and aligns well with our strategy of investing in industry leaders with strong growth potential. We are excited to partner with the RadiciGroup team to strengthen competitive positioning, drive operational excellence and unlock new growth opportunities for the business.”
Angelo Radici and Maurizio Radici, President and Vice President of RadiciGroup, also on behalf of the heirs of Paolo Radici, added, “We are very proud of the growth path achieved by RadiciGroup from its foundation until today. The agreement with Lone Star Fundsmarks the beginning of a new chapter in the global expansion of RadiciGroup’s Specialty Chemicals and High Performance Polymers businesses which boast a strong mutual integration. In a constantly evolving market environment, Lone Star Funds’ experience in the chemical sector, combined with its strategic resources and global expertise/reach, will be key factors in supporting the further business growth, while ensuring continued excellence in serving customers. The Radici family will continue to drive the Advanced Textile Solutions Business Area focusing on innovation and sustainability."
The transaction is expected to close in the second half of 2025, subject to customary closing conditions and regulatory approvals.
About Lone Star
Lone Star is a leading private equity firm advising funds that invest globally in corporate equity, credit, real estate and other financial assets. Since the establishment of its first fund in 1995, Lone Star has organized 25 private equity funds with aggregate capital commitments totaling approximately $95 billion. The firm organizes its funds in three series: the Opportunity Fund series; the Commercial Real Estate Fund series; and the U.S. Residential Mortgage Fund series. Lone Star invests on behalf of its limited partners, which include institutional investors such as pension funds and sovereign wealth funds, as well as foundations and endowments that support medical research, higher education, and other philanthropic causes. For more information regarding Lone Star Funds, go to www.lonestarfunds.com.
About RadiciGroup
With 3,000 employees, sales of €1,069 million in 2023, and a network of production units and sales offices across Europe, North and South America, and Asia, RadiciGroup is a global leader in the production of a wide range of chemical intermediates, polyamide polymers, high-performance engineering polymers, and advanced textile solutions. Operating through its three macro Business Areas - Specialty Chemicals, High Performance Polymers and Advanced Textile Solutions - RadiciGroup provides materials for a diverse range of industrial sectors, including automotive, electrics/electronic, consumer goods, clothing, furniture, construction, household appliances, and sport. At the core of the Group’s strategy are innovation, quality, and customer satisfaction, all pursued in alignment with ESG principles. For more information www.radicigroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224145829/en/
Contacts
mediarelations@lonestarfunds.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom